The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: Comparison of different strategies

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 11, 2013, Pages 2151-2160

  Bonroy, Carolien ^a   Smith, Vanessa ^a   Van Steendam, Katleen ^b   Van Praet, Jens ^a   Deforce, Dieter ^b   Devreese, Katrien ^a   De Keyser, Filip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

anti PM Scl; anti RNA polymerase III; antinuclear antibodies; diagnostic algorithm; systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LABORATORY TEST; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ALGORITHMS; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 84886698250     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0211     Document Type: Article

References (30)

1. Van Praet JT, Vander Cruyssen B, Bonroy C, Smith V, Delanghe J, De Keyser F. Validation of a new screening strategy for anti-extractable nuclear antigen antibodies. Clin Exp Rheumatol 2009;27:971-6
2. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011;10:801-8
3. Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, et al. The Belgian systemic sclerosis cohort: Correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39: 2127-33
4. Wiik AS. Anti-nuclear autoantibodies: Clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005;34:260-8
5. Rondeel JM. Immunofluorescence versus ELISA for the detection of antinuclear antigens. Expert Rev Mol Diagn 2002;23:226-32
6. Vos PA, Bast EJ, Derksen RH. Cost-effective detection of non-Antidouble-stranded DNA antinuclear antibody specificities in daily clinical practice. Rheumatology (Oxford) 2006;45: 629-35
7. Van Praet JT, Van Steendam K, Smith V, De Bruyne G, Mimori T, Bonroy C, et al. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: An extended methodological approach. Rheumatology (Oxford) 2011;50:1302-9
8. Bonroy C, Smith V, Van Steendam K, Van Praet J, Deforce D, Devreese K, et al. Fluoroenzymeimmunoassay to detect systemic sclerosis-Associated antibodies: Diagnostic performance and correlation with conventional techniques. Clin Exp Rheumatol 2012;30:748-55
9. Bonroy C, Van Praet J, Smith V, Van Steendam K, Mimori T, Deschepper E, et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012;379:53-60
10. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012;12:137-43
11. Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V, et al. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Cim Acta 2010;411:710-3
12. Hanke K, Bruckner CS, Dahnrich C, Huscher D, Komorowski L, Meyer W, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009;11:R22
13. Maes L, Blockmans D, Verschueren P, Westhovens R, De Beeck KO, Vermeersch P, et al. Anti-PM/Scl-100 and anti-RNApolymerase III antibodies in scleroderma. Clin Cim Acta 2010;411:965-71
14. Pottel H, Wiik A, Locht H, Gordon T, Roberts-Thomson P, Abraham D, et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004;22:579-88
15. Meheus L, van Venrooij WJ, Wiik A, Charles PJ, Tzioufas AG, Meyer O, et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 1999;17: 205-14
16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5
17. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
19. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
21. Altman RD. Classification of disease: Osteoarthritis. Semin Arthritis Rheum 1991;20(Suppl 2):40-7
22. Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63:1155-8
23. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-Articular manifestations. Ann Rheum Dis 2004;63:1587-93
24. Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171-6
25. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009;8:543-8
26. Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012;12:114-20
27. Damoiseaux JG, Tervaert JW. From ANA to ENA: How to proceed? Autoimmun Rev 2006;5:10-7
28. Vermeersch P, Vervaeke S, Blockmans D, van Hoovels L, Marien G, Vanmaele H, et al. Determination of anti-neutrophil cytoplasmic antibodies in small vessel vasculitis: Comparative analysis of different strategies. Clin Cim Acta 2008;397: 77-81
29. van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods 1991;140:181-9
30. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: A systematic literature review. Semin Arthritis Rheum 2008;37:223-35